Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults

OBJECTIVE: Dolutegravir plus lamivudine (2-DR) is suggested as an initial and switch option in HIV-1 treatment. The aim of this study was to analyze the effectiveness, durability, and safety of 2-DR compared to bictegravir/emtricitabine/tenofovir alafenamide (3-DR). PATIENTS AND METHODS: This was an...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendoza, Inés, Lázaro, Alicia, Espinosa, Alfredo, Sánchez, Lorenzo, Horta, Ana María, Torralba, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540944/
https://www.ncbi.nlm.nih.gov/pubmed/37773939
http://dx.doi.org/10.1371/journal.pone.0291480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540944/
https://www.ncbi.nlm.nih.gov/pubmed/37773939
http://dx.doi.org/10.1371/journal.pone.0291480

Ejemplares similares